In Vitro Study of Combined Application of Bevacizumab and 5-Fluorouracil or Bevacizumab and Mitomycin C to Inhibit Scar Formation in Glaucoma Filtration Surgery

Overview

Journal J Ophthalmol

Publisher Wiley

Specialty Ophthalmology

Date 2019 Dec 31

PMID 31885893

Citations 3

Authors

Yuanyuan Zhang

Shaopin Zhu

Xun Xu

Lei Zuo

Affiliations

Soon will be listed here.

Abstract

This is an in vitro study conducted to observe the safety and antiscarring effects of combined application of bevacizumab (BVZ) and 5-fluorouracil (5-Fu) or BVZ and mitomycin C (MMC) during glaucoma filtration surgery (GFS). The cytotoxicity of drug combinations in human Tenon's fibroblasts (HTFs) and human umbilical vein endothelial cells (HUVECs) was evaluated. Their effects on the levels of vascular endothelial growth factor (VEGF) in HUVECs, cell proliferation and migration in HTFs, and the expression of collagen type I alpha 1 (Col1A1) gene in HTFs were evaluated. In addition, the effects of combined drugs on VEGF(R) mRNA in HTFs were detected to explore the possible underlying drug mechanisms. The results showed that BVZ combined with 5-Fu demonstrated more significant antiscarring effects than BVZ or 5-Fu alone. However, the inhibitory effects of BVZ combined with MMC were similar to those of MMC alone. The cytotoxicity of the drug combinations was significantly greater than that of single drug, suggesting that combined application of BVZ and antimetabolites after GFS was safer when applied at different sites (such as subconjunctival injection at bilateral sides of the filtering bleb) or at varied time points.

Citing Articles

Microwave biosensor for the detection of growth inhibition of human liver cancer cells at different concentrations of chemotherapeutic drug.

Zhao J, Wang Y, Shi B, Wang Y, Jiang Y, Yang G Front Bioeng Biotechnol. 2024; 12:1398189.

PMID: 38803847 PMC: 11128630. DOI: 10.3389/fbioe.2024.1398189.

Anti-scarring effects of conbercept on human Tenon's fibroblasts: comparisons with bevacizumab.

Zuo L, Zhu S, Gu S, Xu X BMC Ophthalmol. 2023; 23(1):183.

PMID: 37101202 PMC: 10131424. DOI: 10.1186/s12886-023-02914-4.

Novel Therapies for the Prevention of Fibrosis in Glaucoma Filtration Surgery.

Shao C, Sinha N, Mohan R, Webel A Biomedicines. 2023; 11(3.

PMID: 36979636 PMC: 10045591. DOI: 10.3390/biomedicines11030657.

References

Tripathi R, Li J, Tripathi B, Chalam K, Adamis A . Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998; 105(2):232-7. DOI: 10.1016/s0161-6420(98)92782-8. View

ONeill E, Qin Q, Van Bergen N, Connell P, Vasudevan S, Coote M . Antifibrotic activity of bevacizumab on human Tenon's fibroblasts in vitro. Invest Ophthalmol Vis Sci. 2010; 51(12):6524-32. DOI: 10.1167/iovs.10-5669. View

Seibold L, Sherwood M, Kahook M . Wound modulation after filtration surgery. Surv Ophthalmol. 2012; 57(6):530-50. DOI: 10.1016/j.survophthal.2012.01.008. View

Vinores S, Chan C, Vinores M, Matteson D, Chen Y, Klein D . Increased vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGFbeta) in experimental autoimmune uveoretinitis: upregulation of VEGF without neovascularization. J Neuroimmunol. 1998; 89(1-2):43-50. DOI: 10.1016/s0165-5728(98)00075-7. View

Vandewalle E, Abegao Pinto L, Van Bergen T, Spielberg L, Fieuws S, Moons L . Intracameral bevacizumab as an adjunct to trabeculectomy: a 1-year prospective, randomised study. Br J Ophthalmol. 2013; 98(1):73-8. DOI: 10.1136/bjophthalmol-2013-303966. View

Skuta G, Beeson C, Higginbotham E, Lichter P, Musch D, Bergstrom T . Intraoperative mitomycin versus postoperative 5-fluorouracil in high-risk glaucoma filtering surgery. Ophthalmology. 1992; 99(3):438-44. DOI: 10.1016/s0161-6420(92)31951-7. View

Tong J, Lam D, Chan W, Choy K, Chan K, Pang C . Effects of triamcinolone on the expression of VEGF and PEDF in human retinal pigment epithelial and human umbilical vein endothelial cells. Mol Vis. 2006; 12:1490-5. View

Saeed A, AboulNasr T . Subconjunctival bevacizumab to augment trabeculectomy with mitomycin C in the management of failed glaucoma surgery. Clin Ophthalmol. 2014; 8:1745-55. PMC: 4168860. DOI: 10.2147/OPTH.S67730. View

Takihara Y, Inatani M, Kawaji T, Fukushima M, Iwao K, Iwao M . Combined intravitreal bevacizumab and trabeculectomy with mitomycin C versus trabeculectomy with mitomycin C alone for neovascular glaucoma. J Glaucoma. 2010; 20(3):196-201. DOI: 10.1097/IJG.0b013e3181d9ce12. View

10.

Bao P, Kodra A, Tomic-Canic M, Golinko M, Ehrlich H, Brem H . The role of vascular endothelial growth factor in wound healing. J Surg Res. 2008; 153(2):347-58. PMC: 2728016. DOI: 10.1016/j.jss.2008.04.023. View

11.

Park S, Jeong M, Ha K, Jang S . Structure and function of vascular endothelial growth factor and its receptor system. BMB Rep. 2018; 51(2):73-78. PMC: 5836560. DOI: 10.5483/bmbrep.2018.51.2.233. View

12.

Vahedian Z, Mafi M, Fakhraie G, Zarei R, Eslami Y, Ghadimi H . Short-term Results of Trabeculectomy Using Adjunctive Intracameral Bevacizumab Versus Mitomycin C: A Randomized Controlled Trial. J Glaucoma. 2017; 26(9):829-834. DOI: 10.1097/IJG.0000000000000741. View

13.

Jurkowska-Dudzinska J, Kosior-Jarecka E, Zarnowski T . Comparison of the use of 5-fluorouracil and bevacizumab in primary trabeculectomy: results at 1 year. Clin Exp Ophthalmol. 2011; 40(4):e135-42. DOI: 10.1111/j.1442-9071.2011.02608.x. View

14.

Spitzer M, Wallenfels-Thilo B, Sierra A, Yoeruek E, Peters S, Henke-Fahle S . Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol. 2006; 90(10):1316-21. PMC: 1857456. DOI: 10.1136/bjo.2006.095190. View

15.

Murakami M, Iwai S, Hiratsuka S, Yamauchi M, Nakamura K, Iwakura Y . Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. Blood. 2006; 108(6):1849-56. DOI: 10.1182/blood-2006-04-016030. View

16.

Pieramici D, Rabena M . Anti-VEGF therapy: comparison of current and future agents. Eye (Lond). 2008; 22(10):1330-6. DOI: 10.1038/eye.2008.88. View

17.

Beddy D, Watson R, Fitzpatrick J, OConnell P . Increased vascular endothelial growth factor production in fibroblasts isolated from strictures in patients with Crohn's disease. Br J Surg. 2004; 91(1):72-7. DOI: 10.1002/bjs.4453. View

18.

Grehn F, Hollo G, Khaw P, Overton B, Wilson R, Vogel R . Factors affecting the outcome of trabeculectomy: an analysis based on combined data from two phase III studies of an antibody to transforming growth factor beta2, CAT-152. Ophthalmology. 2007; 114(10):1831-8. DOI: 10.1016/j.ophtha.2007.06.028. View

19.

Kakehashi A, Inoda S, Mameuda C, Kuroki M, Jono T, Nagai R . Relationship among VEGF, VEGF receptor, AGEs, and macrophages in proliferative diabetic retinopathy. Diabetes Res Clin Pract. 2007; 79(3):438-45. DOI: 10.1016/j.diabres.2007.10.018. View

20.

Roskoski Jr R . VEGF receptor protein-tyrosine kinases: structure and regulation. Biochem Biophys Res Commun. 2008; 375(3):287-91. DOI: 10.1016/j.bbrc.2008.07.121. View